文献速递肿瘤 PET/CT

[68Ga]Ga-FAPI-04与[18F]-FDG PET/CT在胃腺癌病变范围评估中的头对头比较

Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-07-24

该前瞻性头对头研究在同一组13例胃腺癌患者中比较了FAPI与FDG PET/CT,其中初诊分期10例、再分期3例。结果显示FAPI对原发胃肿瘤和腹膜癌变的检出率优于FDG,肿瘤/本底比值更高,但对区域淋巴结受累的检出率相当。FAPI在腹膜癌变化疗后疗效监测中显示潜力,但需更大规模试验验证。

要点

  • FAPI对原发胃肿瘤检出率为100%,FDG为50%。
  • FAPI对腹膜癌变检出率100%,FDG未见检出。
  • FAPI肿瘤/本底比值显著高于FDG(P=0.007)。

核心结论

  • FAPI PET/CT在检测原发胃腺癌和腹膜癌变方面优于FDG PET/CT。
  • FAPI PET/CT在腹膜癌变化疗后疗效监测中显示潜力,但需更大规模试验验证。

研究设计与样本

  • 前瞻性头对头比较研究,同一组13例胃腺癌患者接受FAPI与FDG PET/CT,其中初诊分期10例、再分期3例。

主要发现

  • 10例原发胃肿瘤中FAPI全部阳性(检出率100%),FDG仅5例阳性(50%)。
  • FAPI与FDG的SUVmax无显著差异,但FAPI肿瘤/本底比值更高(FDG均值4.5、中位数3.2、范围0.8-9.7;FAPI均值12.9、中位数11.9、范围2.2-23.9;P=0.007)。
  • 区域淋巴结受累检出率两者相当。
  • FAPI对腹膜癌变检出率100%,FDG未见检出。
  • 2例广泛腹膜癌变患者化疗后复查FAPI,1例部分缓解、1例疾病进展。

临床怎么用

  • 在胃腺癌分期中,FAPI PET/CT可提高原发肿瘤和腹膜癌变的检出,尤其适用于FDG阴性或怀疑腹膜转移的患者。
  • FAPI PET/CT可用于腹膜癌变患者化疗后的疗效监测。

局限性

  • 本研究为初步小样本研究(13例),需更大规模试验验证初步发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: [18F]-Fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) may sometimes be suboptimal for imaging gastric adenocarcinoma. The recently introduced [68Ga]Ga-FAPI-04 (FAPI) PET/CT targets tumor stroma and has shown considerable potential in evaluating the extent of disease in a variety of tumors. METHODS: We performed a head-to-head prospective comparison of FAPI and FDG PET/CT in the same group of 13 patients with gastric adenocarcinoma who presented for either initial staging (n = 10) or restaging (n = 3) of disease. Lesion detection and maximum standardized uptake value (SUVmax) were compared between the two types of radiotracers. RESULTS: All ten primary gastric tumors were FAPI-positive (100% detection rate), whereas only five were also FDG-positive (50%). SUVmax was not significantly different, but the tumor-to-background ratio was higher for FAPI (mean, median, and range of 4.5, 3.2, and 0.8-9.7 for FDG and 12.9, 11.9, and 2.2-23.9 for FAPI, P = 0.007). The level of detection of regional lymph node involvement was comparable. FAPI showed a superior detection rate for peritoneal carcinomatosis (100% vs. none). Two patients with widespread peritoneal carcinomatosis underwent a follow-up FAPI scan after chemotherapy: one showed partial remission and the other showed progressive disease. CONCLUSIONS: The findings of this pilot study suggest that FAPI PET/CT outperforms FDG PET/CT in detecting both primary gastric adenocarcinoma and peritoneal carcinomatosis from gastric cancer. FAPI PET/CT also shows promise for monitoring response to treatment in patients with peritoneal carcinomatosis from gastric cancer; however, larger trials are needed to validate these preliminary findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kuten J, Levine C, Shamni O, et al. Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021. PMID: 34302504. doi:10.1007/s00259-021-05494-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。